PTGS2 and melanoma: As COX-2 is a downstream target of NF-κB pathway, we further checked the effect of GSPs on the basal levels of NF-κB in melanoma cells, and found that treatment of melanoma cells with GSPs results in inactivation of NF-κB pathway in a dose-dependent manner.